AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.91 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
Pre-Market: $3.99 +0.08 (2.05%) 9:20 AM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ACIU 3.91 0.00(0.00%)
Will ACIU be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACIU
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
Other News for ACIU
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug
AC Immune's ACI-35.030 granted FDA Fast Track Designation
AC Immune?s ACI-35.030 (now ?JNJ-2056?) Granted FDA Fast Track Designation for Alzheimer?s Disease
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024